中性粒细胞百分比、淋巴细胞百分比对肺腺癌EGFR-TKI靶向治疗预后的预测价值
Prognosis assessment value of neutrophil percentage and lymphocyte percentage for lung adenocarcinoma patients with EGFR-TKI targeted therapy

目的:探讨中性粒细胞百分比、淋巴细胞百分比对肺腺癌表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)靶向治疗预后的预测价值。方法:收集162例接受EGFR-TKI靶向治疗的肺腺癌患者的治疗资料和随访资料,采用Cox回归模型分析预后的影响因素。结果:162例中,18、19、20、21位点突变分别有4、81、11和66例。治疗前162例患者中性粒细胞百分比(62.90±12.58)%,其中在正常范围130例,降低8例,升高24例; 淋巴细胞百分比(25.39±10.89)%,其中在正常范围102例,降低48例,升高12例。Cox回归分析结果显示,以EGFR基因突变类型为分层因素,在调整年龄、性别因素后,治疗前淋巴细胞百分比升高可降低肺腺癌EGFR-TKI靶向治疗的不良预后风险(HR=0.934,95%CI 为0.884～0.987)。结论:淋巴细胞百分比可能是一个重要的肺癌EGFR-TKI靶向治疗预后预测因子。
Aim: To investigate the prognosis assessment value of neutrophil percentage and lymphocyte percentage for lung adenocarcinoma patients with EGFR-TKI targeted therapy.Methods:The data of 162 lung adenocarcinoma patients treated with EGFR-TKI were analyzed retrospectively.The relationship between neutrophil percentage,lymphocyte percentage and prognosis was assessed by Cox regression analysis.Results:Out of the 162 cases,there were 4,81,11 and 66 mutation cases at positions 18,19,20 and 21,respectively.Before treatment,the neutrophil percentage in 162 patients was(62.90±12.58)%,in which 130 cases were normal,8 were decreased,and 24 were increased; the lymphocyte percentage was(25.39±10.89)%,in which 102 cases were normal,48 were decreased,and 11 were increased.Cox regression analysis showed that,with EGFR gene mutation as a stratification factor,after adjusting age and gender,the increase of pretreatment lymphocyte percentage could reduce the adverse prognosis risk(HR=0.934,95%CI was 0.884 to 0.987).Conclusion: Lymphocyte percentage may be an important biomarker for the prognosis assessment of lung adenocarcinoma patients with EGFR-TKI targeted therapy